ストックスクリーナーアプリを入手
2.63
7.72%
-0.22
アフターアワーズ：
2.69
0.06
+2.28%
前日終値:
$2.85
開ける：
$2.79
24時間の取引高:
692.71K
Relative Volume:
0.95
時価総額：
$166.62M
収益：
$13.86M
当期純損益:
$-81.74M
株価収益率:
-2.0175
EPS:
-1.3036
ネットキャッシュフロー:
$-66.98M
1週間 パフォーマンス:
+17.94%
1か月 パフォーマンス:
+53.80%
6か月 パフォーマンス:
+128.70%
1年 パフォーマンス:
+119.17%
1日の値動き範囲:
$2.63
$3.00
1週間の範囲:
$2.2019
$3.40
52週間の値動き範囲:
$0.97
$5.55
Pyxis Oncology Inc Stock (PYXS) Company Profile
Compare PYXS vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PYXS
Pyxis Oncology Inc
|
2.63 | 190.70M | 13.86M | -81.74M | -66.98M | -1.3036 |
VRTX
Vertex Pharmaceuticals Inc
|
528.04 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
654.27 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
939.68 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
312.78 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.24 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pyxis Oncology Inc Stock (PYXS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-03 | 再開されました | Stifel | Buy |
| 2025-09-04 | 開始されました | Guggenheim | Buy |
| 2024-11-21 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2024-11-08 | 開始されました | Stephens | Overweight |
| 2024-08-08 | 開始されました | Stifel | Buy |
| 2024-05-07 | 再開されました | Jefferies | Buy |
| 2024-02-09 | 開始されました | BTIG Research | Buy |
| 2024-01-23 | 開始されました | Leerink Partners | Outperform |
| 2023-09-05 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-11-02 | 開始されました | BofA Securities | Neutral |
| 2021-11-02 | 開始されました | Credit Suisse | Outperform |
| 2021-11-02 | 開始されました | Jefferies | Buy |
すべてを表示
Pyxis Oncology Inc (PYXS) 最新ニュース
Leerink cuts Pyxis Oncology stock price target on valuation By Investing.com - Investing.com Canada
Pyxis Oncology, Inc. Financial Disclosures & SEC Filings - TradingView
Pyxis Oncology Secures $114M for MICVO Cancer Trial - AllSci
Pyxis Oncology, Inc. Stock 12‑Month Price Target Raised to $7.14, Implies 137% Upside - TradingView
Latham & Watkins Advises on Pyxis Oncology’s Up to US$114 Million Private Placement Financing - Legal Desire Media and Insights
Latham Advises on Pyxis Oncology Up to Private Placement Financing - Latham & Watkins LLP
William Blair Maintains Pyxis Oncology(PYXS.US) With Hold Rating - Moomoo
[144] Pyxis Oncology, Inc. SEC Filing - Stock Titan
Pyxis Oncology, Inc. (PYXS) announced the completion of a private financing agreement with a total funding amount up to 114 millions dollars. - Bitget
Pyxis Oncology Announces up to $114 Million P - Moomoo
Pyxis Oncology Secures Up to $114 Million Private Placement - marketscreener.com
Pyxis Oncology (PYXS) Secures $50 Million in Private Placement F - GuruFocus
Pyxis Oncology Announces Up To $114 Million Private Placement Financing To Advance Micvo Through Key Clinical Milestones - TradingView
Pyxis Oncology raises $50 million in private placement - Investing.com
Pyxis Oncology announces up to $114M private placement - TipRanks
Pyxis Oncology raises $50 million in private placement By Investing.com - Investing.com Canada
Pyxis Oncology Announces up to $114 Million Private Placement Financing to Advance Micvo Through Key Clinical Milestones - Moomoo
Pyxis Oncology raises up to $114M to fund MICVO trial updates - Stock Titan
Pyxis Oncology, Inc.(NasdaqGS:PYXS) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Pyxis Oncology, Inc.(NasdaqGS:PYXS) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Pyxis Oncology, Inc.(NasdaqGS: PYXS) added to Russell 3000E Growth Benchmark - marketscreener.com
PYXS Stock Price, Quote & Chart - ChartMill
Pyxis Oncology, Inc. Actuals & Estimates (NASDAQ:PYXS) - TradingView
PYXS Forecast — Price Target — Prediction for 2027 - TradingView
Pyxis Oncology Inc (PYXS) Institutional Confidence - TradingKey
Pyxis Oncology Inc (PYXS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Pyxis Oncology Inc (PYXS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Penny Stocks To Watch For Growth In June 2026 - simplywall.st
Pyxis Oncology StockThursday technicals around key trading levels - AD HOC NEWS
Pyxis Oncology Inc (PYXS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Pyxis Oncology Inc (PYXS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Pyxis Oncology Inc (PYXS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Pyxis Oncology (PYXS) Surges 6.8% as Momentum Builds Near Key ResistanceMax Pain Level - dars.gov.et
Pyxis Oncology Inc (PYXS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Pyxis Oncology Inc (PYXS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Pyxis Oncology Inc (PYXS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Pyxis Oncology, Inc. Files Form 8-K with SEC Detailing Corporate Information and Emerging Growth Status - Minichart
Pyxis Oncology elects directors and ratifies auditor at annual meeting - Investing.com
Pyxis Oncology elects directors and ratifies auditor at annual meeting By Investing.com - Investing.com UK
Pyxis Oncology Stockholders Approve Directors and Auditor Slate - TipRanks
Pyxis Oncology (PYXS) shareholders elect Class II directors and ratify Ernst & Young as 2026 auditor - Stock Titan
Pyxis Oncology Inc. (PYXS) Q1 2026 Earnings: Narrower Loss Beats Estimates as Stock Rises on Clinical ProgressFree Cash Flow Trends - newsline.com
Analysts See Nearly 3X Upside in Pyxis Oncology (PYXS) - Insider Monkey
PYXS Q1 2026 Earnings: Narrower-Than-Expected Loss Supports Stock UptickEarnings Quality Analysis - newsline.com
Number of shareholders of Pyxis Oncology, Inc. – NASDAQ:PYXS - TradingView
Pyxis Oncology, Inc. - MLQ.ai
Pyxis Oncology Stock Draws Attention Again After Jefferies as Traders Eye MICVO Results - Bez Kabli
PYXS: Mid-year data will clarify MICVO's efficacy, safety, and pivotal trial path in head and neck cancer - TradingView
HC Wainwright & Co. maintains Pyxis Oncology (PYXS) buy recommendation - MSN
PYXS: Mid-year data will highlight MICVO's efficacy and safety in head and neck cancer, supporting pivotal plans - TradingView
Pyxis Oncology Inc. (PYXS) Q1 2026 Earnings: Narrower-than-expected loss as clinical pipeline advancesProfit Guidance Range - newsline.com
Pyxis Oncology Inc (PYXS) 財務データ
収益
当期純利益
現金流量
EPS
3.86%
大文字化:
|
ボリューム (24 時間):